Covid19_DB Summaries
The data below summarises information on interventonal trials for included in Covid19_DB, a curated listing of interventional clinical trials in Covid-19/2019-nCoV produced by the Anticancer Fund.
A machine-readable version of this database can be downloaded here: Covid19db.txt. The ReDO database of repurposing candidates in oncology can be accessed here: ReDO_DB.
Important note for patients:This list includes trials of drugs that, based on their scientific properties, warrant further scientific investigation. In many cases the existing scientific evidence for their effects on coronavirus infection is very limited. Further scientific and clinical research is needed before any statements regarding their therapeutic activity can be made. This list is not intended to be used as a source for possible treatment options for patients.
If you need help exploring further treatment options for your situation, please contact your local medical services at the first instance.
* For international trials, only the country of the primary sponsor is indicated. This causes an underestimation of the number of trials running in each country. For instance, the WHO Solidarity trial is running at least in Argentina, Brazil, Canada, Germany, Indonesia, Iran, Norway, Peru, Qatar, South Africa, Spain, Switzerland & Thailand but is attributed to Switzerland as the WHO Swiss headquarters registered the trial.
Summary results as of last build on: 20/08/2020 09:45
Prevention Trials - Summary
| All drug-based trials in Dataset | 1618 | |
| Prevention Trials | N | % |
| Total | 202 | 12.5% |
| Controlled Trials | N | % |
| Yes | 168 | 83.2% |
| No | 34 | 16.8% |
| Country PI | N | % |
| United States | 45 | 22.3% |
| China | 18 | 8.9% |
| India | 16 | 7.9% |
| Spain | 15 | 7.4% |
| Iran | 13 | 6.4% |
| Canada | 11 | 5.4% |
| United Kingdom | 9 | 4.5% |
| Australia | 7 | 3.5% |
| Mexico | 6 | 3.0% |
| Egypt | 5 | 2.5% |
| Netherlands | 5 | 2.5% |
| France | 4 | 2.0% |
| Brazil | 3 | 1.5% |
| Germany | 3 | 1.5% |
| Denmark | 3 | 1.5% |
| Cuba | 3 | 1.5% |
| Korea, Republic of | 3 | 1.5% |
| Russian Federation | 2 | 1.0% |
| Pakistan | 2 | 1.0% |
| Colombia | 2 | 1.0% |
| Argentina | 2 | 1.0% |
| Tunisia | 2 | 1.0% |
| Singapore | 2 | 1.0% |
| Austria | 2 | 1.0% |
| United Arab Emirates | 2 | 1.0% |
| South Africa | 2 | 1.0% |
| Italy | 1 | 0.5% |
| Japan | 1 | 0.5% |
| Switzerland | 1 | 0.5% |
| Belgium | 1 | 0.5% |
| Israel | 1 | 0.5% |
| Greece | 1 | 0.5% |
| Poland | 1 | 0.5% |
| Chile | 1 | 0.5% |
| Qatar | 1 | 0.5% |
| Peru | 1 | 0.5% |
| Jordan | 1 | 0.5% |
| Hungary | 1 | 0.5% |
| Philippines | 1 | 0.5% |
| Kenya | 1 | 0.5% |
| Sri Lanka | 1 | 0.5% |
| Population | N | % |
| At risk (HCP or family members) | 117 | 57.9% |
| Not at risk | 85 | 42.1% |
| Intervention type | N | % |
| Drug Repurposing | 122 | 60.4% |
| Vaccine | 63 | 31.2% |
| Shelved drug or NME | 22 | 10.9% |
| Cell/Blood based | 2 | 1.0% |
| Other (add comment) | 1 | 0.5% |
| Products | N | % |
| Hydroxychloroquine | 76 | 37.6% |
| Vaccine | 46 | 22.8% |
| BCG Vaccine | 12 | 5.9% |
| Vitamin D | 6 | 3.0% |
| Chloroquine | 4 | 2.0% |
| Ivermectin | 4 | 2.0% |
| Vitamin D3 | 4 | 2.0% |
| Nitazoxanide | 4 | 2.0% |
| Zinc | 4 | 2.0% |
| Povidone-Iodine | 4 | 2.0% |
| Lopinavir | 4 | 2.0% |
| Azithromycin | 3 | 1.5% |
| Lopinavir/ritonavir | 3 | 1.5% |
| Interferon | 3 | 1.5% |
| Favipiravir | 2 | 1.0% |
| Ascorbic acid | 2 | 1.0% |
| Melatonin | 2 | 1.0% |
| Bromhexine | 2 | 1.0% |
| Ritonavir | 2 | 1.0% |
| Interferon alpha | 2 | 1.0% |
| Magnesium | 2 | 1.0% |
| Adenoviral vaccine | 2 | 1.0% |
| Mycobacterium | 2 | 1.0% |
| Convalescent plasma | 2 | 1.0% |
| BNT162b1 | 2 | 1.0% |
| MR Vaccine | 2 | 1.0% |
| INO-4800 | 2 | 1.0% |
| BNT162 vaccine | 2 | 1.0% |
| Emtricitabine | 2 | 1.0% |
| Umifenovir | 1 | 0.5% |
| Nitric oxide | 1 | 0.5% |
| Levamisole | 1 | 0.5% |
| Darunavir | 1 | 0.5% |
| LY3819253 | 1 | 0.5% |
| Thymosin alpha | 1 | 0.5% |
| Thymalfasin | 1 | 0.5% |
| Tenofovir | 1 | 0.5% |
| Mefloquine | 1 | 0.5% |
| PUL-042 | 1 | 0.5% |
| Interferon alpha 1b | 1 | 0.5% |
| Peg-Interferon lambda-1a | 1 | 0.5% |
| Isoprinosine | 1 | 0.5% |
| GX-19 | 1 | 0.5% |
| Lopinavir-Ritonavir | 1 | 0.5% |
| Mucodentol | 1 | 0.5% |
| MMRII Vaccine | 1 | 0.5% |
| Bisphosphonate | 1 | 0.5% |
| Previfenon | 1 | 0.5% |
| MV130 | 1 | 0.5% |
| Icosapent ethyl | 1 | 0.5% |
| Alendronic acid | 1 | 0.5% |
| BBV152 Vaccine | 1 | 0.5% |
| Covax-19 vaccine | 1 | 0.5% |
| Inactivated SARS-CoV-2 vaccine | 1 | 0.5% |
| MMR Vaccine | 1 | 0.5% |
| TMV-083 Vaccine | 1 | 0.5% |
| IMM-101 | 1 | 0.5% |
| Paracetamol | 1 | 0.5% |
| Emtricitabine/Tenofovir Alafenamide | 1 | 0.5% |
| GLS-1200 | 1 | 0.5% |
| AG0301 Vaccine | 1 | 0.5% |
| Immuno-1 | 1 | 0.5% |
| Immuno-2 | 1 | 0.5% |
| KBP-201 Vaccine | 1 | 0.5% |
| mRNA-1273 vaccine | 1 | 0.5% |
| Vitamin K | 1 | 0.5% |
| AZD1222 | 1 | 0.5% |
| BCG Vaccine | 1 | 0.5% |
| SARS-CoV-2 Sclamp Protein Subunit Vaccine | 1 | 0.5% |
| BNT162b2 | 1 | 0.5% |
| Measles Vaccine | 1 | 0.5% |
| Ritonavir/lopinavir | 1 | 0.5% |
| Emtricitabine/tenofovir | 1 | 0.5% |
| bacTRL-Spike vaccine | 1 | 0.5% |
| Nitric Oxide Releasing Solution | 1 | 0.5% |
| Matrix-M Adjuvant | 1 | 0.5% |
| CIGB 2020 vaccine | 1 | 0.5% |
| Interferon lambda | 1 | 0.5% |
| Prazosin | 1 | 0.5% |
| Peg-Interferon lambda | 1 | 0.5% |
| Thymosin | 1 | 0.5% |
| SARS-CoV-2 rS Vaccine | 1 | 0.5% |
| Primary Endpoint | N | % |
| Infection rate | 130 | 64.4% |
| Safety | 40 | 19.8% |
| Other | 32 | 15.8% |
Therapeutic Trials - Summary
| All drug-based trials in Dataset | 1618 | |
| Treatment Trials | N | % |
| Total | 1409 | 87.1% |
| Controlled Trials | N | % |
| Yes | 1145 | 81.3% |
| No | 264 | 18.7% |
| Trial tests >1 intervention | N | % |
| Yes | 159 | 11.3% |
| No | 1250 | 88.7% |
| Country PI | N | % |
| United States | 346 | 24.6% |
| China | 198 | 14.1% |
| Iran | 173 | 12.3% |
| Spain | 83 | 5.9% |
| France | 58 | 4.1% |
| India | 48 | 3.4% |
| Brazil | 46 | 3.3% |
| United Kingdom | 44 | 3.1% |
| Italy | 43 | 3.1% |
| Egypt | 42 | 3.0% |
| Mexico | 29 | 2.1% |
| Canada | 22 | 1.6% |
| Germany | 20 | 1.4% |
| Australia | 15 | 1.1% |
| Netherlands | 13 | 0.9% |
| Russian Federation | 13 | 0.9% |
| Pakistan | 13 | 0.9% |
| Denmark | 12 | 0.9% |
| Colombia | 12 | 0.9% |
| Japan | 12 | 0.9% |
| Switzerland | 12 | 0.9% |
| Belgium | 12 | 0.9% |
| Israel | 9 | 0.6% |
| Argentina | 8 | 0.6% |
| Greece | 8 | 0.6% |
| Saudi Arabia | 8 | 0.6% |
| Sweden | 8 | 0.6% |
| Cuba | 7 | 0.5% |
| Korea, Republic of | 6 | 0.4% |
| Bangladesh | 6 | 0.4% |
| Nigeria | 5 | 0.4% |
| Turkey | 5 | 0.4% |
| Hong Kong | 5 | 0.4% |
| Thailand | 4 | 0.3% |
| Tunisia | 3 | 0.2% |
| Singapore | 3 | 0.2% |
| Poland | 3 | 0.2% |
| Chile | 3 | 0.2% |
| Qatar | 3 | 0.2% |
| Ireland | 3 | 0.2% |
| Iraq | 3 | 0.2% |
| Indonesia | 3 | 0.2% |
| Austria | 2 | 0.1% |
| Peru | 2 | 0.1% |
| Jordan | 2 | 0.1% |
| Senegal | 2 | 0.1% |
| Iceland | 2 | 0.1% |
| Guinea | 2 | 0.1% |
| Viet Nam | 2 | 0.1% |
| Malaysia | 2 | 0.1% |
| Ukraine | 2 | 0.1% |
| Finland | 2 | 0.1% |
| Norway | 2 | 0.1% |
| Bahrain | 2 | 0.1% |
| Ecuador | 2 | 0.1% |
| Hungary | 1 | 0.1% |
| New Zealand | 1 | 0.1% |
| Madagascar | 1 | 0.1% |
| Portugal | 1 | 0.1% |
| Ivory Coast | 1 | 0.1% |
| Ghana | 1 | 0.1% |
| Belarus | 1 | 0.1% |
| Kuwait | 1 | 0.1% |
| Macedonia, the former Yugoslav Republic of | 1 | 0.1% |
| Taiwan | 1 | 0.1% |
| Slovenia | 1 | 0.1% |
| Bosnia and Herzegovina | 1 | 0.1% |
| Czech Republic | 1 | 0.1% |
| Bulgaria | 1 | 0.1% |
| Population | ||
| (Total>N as trials can include both mild and severe cases) | N | % |
| Severe Cases | 1056 | 74.9% |
| Mild/Moderate Cases | 976 | 69.3% |
| Other (add comment) | 62 | 4.4% |
| General population | 8 | 0.6% |
| Exposed individuals (family members, HCP) | 5 | 0.4% |
| Intervention type | N | % |
| Drug Repurposing | 908 | 64.4% |
| Cell/Blood based | 277 | 19.7% |
| Shelved drug or NME | 244 | 17.3% |
| Other (add comment) | 15 | 1.1% |
| Vaccine | 8 | 0.6% |
| TCM | 1 | 0.1% |
| Products | N | % |
| Convalescent plasma | 143 | 10.1% |
| Hydroxychloroquine | 135 | 9.6% |
| Azithromycin | 62 | 4.4% |
| Tocilizumab | 58 | 4.1% |
| Interferon | 44 | 3.1% |
| Favipiravir | 42 | 3.0% |
| Lopinavir | 41 | 2.9% |
| Chloroquine | 39 | 2.8% |
| Ivermectin | 35 | 2.5% |
| Lopinavir/ritonavir | 33 | 2.3% |
| Methylprednisolone | 31 | 2.2% |
| Ascorbic acid | 26 | 1.8% |
| Enoxaparin | 25 | 1.8% |
| Colchicine | 22 | 1.6% |
| Interferon beta | 22 | 1.6% |
| Ruxolitinib | 19 | 1.3% |
| Sarilumab | 16 | 1.1% |
| Remdesivir | 16 | 1.1% |
| Vitamin D3 | 15 | 1.1% |
| Baricitinib | 15 | 1.1% |
| Immunoglobulin | 15 | 1.1% |
| Vitamin D | 15 | 1.1% |
| Nitazoxanide | 14 | 1.0% |
| Losartan | 14 | 1.0% |
| Dexamethasone | 14 | 1.0% |
| Ritonavir | 14 | 1.0% |
| Zinc | 13 | 0.9% |
| Anakinra | 13 | 0.9% |
| Heparin | 12 | 0.9% |
| N-acetylcysteine | 11 | 0.8% |
| Interferon alpha | 11 | 0.8% |
| Umifenovir | 9 | 0.6% |
| Camostat | 9 | 0.6% |
| Sofosbuvir | 9 | 0.6% |
| Daclatasvir | 9 | 0.6% |
| Interferon beta-1a | 8 | 0.6% |
| Interferon beta-1b | 8 | 0.6% |
| Oseltamivir | 8 | 0.6% |
| Dornase alfa | 8 | 0.6% |
| Aspirin | 8 | 0.6% |
| Doxycycline | 7 | 0.5% |
| Ribavirin | 7 | 0.5% |
| Clazakizumab | 7 | 0.5% |
| Rivaroxaban | 7 | 0.5% |
| Imatinib | 7 | 0.5% |
| Povidone-Iodine | 6 | 0.4% |
| Atorvastatin | 6 | 0.4% |
| Nafamostat | 6 | 0.4% |
| Azvudine | 6 | 0.4% |
| Ciclesonide | 6 | 0.4% |
| Atazanavir | 6 | 0.4% |
| Vaccine | 6 | 0.4% |
| Melatonin | 5 | 0.4% |
| Bromhexine | 5 | 0.4% |
| Sirolimus | 5 | 0.4% |
| Niclosamide | 5 | 0.4% |
| Interferon alpha-2b | 5 | 0.4% |
| Telmisartan | 5 | 0.4% |
| Mavrilimumab | 5 | 0.4% |
| Budesonide | 5 | 0.4% |
| Nitric oxide | 4 | 0.3% |
| Danoprevir | 4 | 0.3% |
| Cyclosporine | 4 | 0.3% |
| Vitamin A | 4 | 0.3% |
| Deferoxamine | 4 | 0.3% |
| Isotretinoin | 4 | 0.3% |
| Prednisone | 4 | 0.3% |
| Thalidomide | 4 | 0.3% |
| Tofacitinib | 4 | 0.3% |
| Sevoflurane | 4 | 0.3% |
| Alteplase | 4 | 0.3% |
| Acalabrutinib | 4 | 0.3% |
| Leflunomide | 4 | 0.3% |
| Bevacizumab | 4 | 0.3% |
| Siltuximab | 4 | 0.3% |
| Ulinastatin | 4 | 0.3% |
| Naproxen | 4 | 0.3% |
| Hydrocortisone | 4 | 0.3% |
| Nivolumab | 4 | 0.3% |
| Pirfenidone | 4 | 0.3% |
| CYT107 | 4 | 0.3% |
| Mycobacterium | 4 | 0.3% |
| NOS | 4 | 0.3% |
| Levamisole | 3 | 0.2% |
| Darunavir | 3 | 0.2% |
| Trifluoperazine | 3 | 0.2% |
| Cenicriviroc | 3 | 0.2% |
| Maraviroc | 3 | 0.2% |
| Montelukast | 3 | 0.2% |
| Lithium | 3 | 0.2% |
| EIDD-2801 | 3 | 0.2% |
| Adalimumab | 3 | 0.2% |
| Hydoxychloroquine | 3 | 0.2% |
| Tinzaparin | 3 | 0.2% |
| Spironolactone | 3 | 0.2% |
| Clopidogrel | 3 | 0.2% |
| Canakinumab | 3 | 0.2% |
| Metformin | 3 | 0.2% |
| Avdoralimab | 3 | 0.2% |
| Atazanavir/ritonavir | 3 | 0.2% |
| Dexmedetomidine | 3 | 0.2% |
| Artesunate | 3 | 0.2% |
| Tenofovir | 3 | 0.2% |
| Artemisinin | 3 | 0.2% |
| DB-001 | 3 | 0.2% |
| Ledipasvir | 3 | 0.2% |
| Interferon lambda | 3 | 0.2% |
| Thymosin | 3 | 0.2% |
| LY3819253 | 2 | 0.1% |
| Thymosin alpha | 2 | 0.1% |
| Olokizumab | 2 | 0.1% |
| REGN10987 | 2 | 0.1% |
| BDB-001 | 2 | 0.1% |
| Bicalutamide | 2 | 0.1% |
| IMU-838 | 2 | 0.1% |
| Zilucoplan | 2 | 0.1% |
| Cholecalciferol | 2 | 0.1% |
| Duvelisib | 2 | 0.1% |
| C21 | 2 | 0.1% |
| Azythromycine | 2 | 0.1% |
| Lanadelumab | 2 | 0.1% |
| NT-17 | 2 | 0.1% |
| Ibrutinib | 2 | 0.1% |
| rbACE2 | 2 | 0.1% |
| Rosuvastatin | 2 | 0.1% |
| Resveratrol | 2 | 0.1% |
| Dipyridamole | 2 | 0.1% |
| KB109 | 2 | 0.1% |
| Aprepitant | 2 | 0.1% |
| Isoflurane | 2 | 0.1% |
| Ebselen | 2 | 0.1% |
| Apixaban | 2 | 0.1% |
| Poractant alfa | 2 | 0.1% |
| Itolizumab | 2 | 0.1% |
| Enzalutamide | 2 | 0.1% |
| Iloprost | 2 | 0.1% |
| Icatibant | 2 | 0.1% |
| Artemisinin-piperaquine | 2 | 0.1% |
| Razuprotafib | 2 | 0.1% |
| CIGB-258 | 2 | 0.1% |
| EDP1815 | 2 | 0.1% |
| REGN10933 | 2 | 0.1% |
| Sitagliptin | 2 | 0.1% |
| Eculizumab | 2 | 0.1% |
| Pembrolizumab | 2 | 0.1% |
| Defibrotide | 2 | 0.1% |
| Fingolimod | 2 | 0.1% |
| Formoterol | 2 | 0.1% |
| Famotidine | 2 | 0.1% |
| Sargramostim | 2 | 0.1% |
| Sildenafil | 2 | 0.1% |
| Ibuprofen | 2 | 0.1% |
| Nintedanib | 2 | 0.1% |
| Simvastatin | 2 | 0.1% |
| Trimethoprim/sulfamethoxazole | 2 | 0.1% |
| Tacrolimus | 2 | 0.1% |
| Angiotensin Receptor Blockers | 2 | 0.1% |
| Cobicistat | 2 | 0.1% |
| Fondaparinux | 2 | 0.1% |
| Tranexamic acid | 2 | 0.1% |
| Ravulizumab | 2 | 0.1% |
| Valsartan | 2 | 0.1% |
| Budesonide/formoterol | 2 | 0.1% |
| Alpha Lipoic Acid | 2 | 0.1% |
| Captopril | 2 | 0.1% |
| Hydrogen peroxide | 2 | 0.1% |
| Indomethacin | 2 | 0.1% |
| Angiotensin 1-7 | 2 | 0.1% |
| Ledipasvir/sofosbuvir | 2 | 0.1% |
| Tranilast | 2 | 0.1% |
| Leronlimab | 2 | 0.1% |
| Secukinumab | 2 | 0.1% |
| Daclatasvir/sofosbuvir | 2 | 0.1% |
| Prednisolone | 2 | 0.1% |
| Linagliptin | 2 | 0.1% |
| Atovaquone | 2 | 0.1% |
| Progesterone | 2 | 0.1% |
| Aviptadil | 2 | 0.1% |
| Chlorpromazine | 2 | 0.1% |
| Selinexor | 2 | 0.1% |
| Dapagliflozin | 2 | 0.1% |
| Methylene blue | 2 | 0.1% |
| TD-0903 | 2 | 0.1% |
| DAS181 | 2 | 0.1% |
| Folic acid | 2 | 0.1% |
| Bromelain | 2 | 0.1% |
| Nicotinamide | 2 | 0.1% |
| Interferon-beta | 2 | 0.1% |
| Peg-Interferon lambda | 2 | 0.1% |
| BCG Vaccine | 1 | 0.1% |
| Thymalfasin | 1 | 0.1% |
| Mefloquine | 1 | 0.1% |
| PUL-042 | 1 | 0.1% |
| Sofosbuvir/daclatasvir | 1 | 0.1% |
| Interferon alpha 1b | 1 | 0.1% |
| Peg-Interferon lambda-1a | 1 | 0.1% |
| Isoprinosine | 1 | 0.1% |
| MSTT1041A | 1 | 0.1% |
| Iodine complex | 1 | 0.1% |
| Sulfonatoporphyrin | 1 | 0.1% |
| NT-I7 | 1 | 0.1% |
| Alkaline phosphatase | 1 | 0.1% |
| Abatacept | 1 | 0.1% |
| Vitamin B12 | 1 | 0.1% |
| Elman | 1 | 0.1% |
| Zinc Citrate | 1 | 0.1% |
| Tridecactide | 1 | 0.1% |
| JS016 | 1 | 0.1% |
| Astegolimab | 1 | 0.1% |
| Tramadol | 1 | 0.1% |
| CK0802 | 1 | 0.1% |
| N-803 | 1 | 0.1% |
| Pyronaridine/Artesunate | 1 | 0.1% |
| Oxytocin | 1 | 0.1% |
| 1 | 0.1% | |
| Brensocatib | 1 | 0.1% |
| MAS825 | 1 | 0.1% |
| COVID-19 Specific T Cell derived exosomes | 1 | 0.1% |
| INOSARS | 1 | 0.1% |
| Dociparastat | 1 | 0.1% |
| Cholchicine | 1 | 0.1% |
| Nifedipine | 1 | 0.1% |
| Apilimod dimesylate | 1 | 0.1% |
| LB1148 | 1 | 0.1% |
| DUR-928 | 1 | 0.1% |
| Lucinactant | 1 | 0.1% |
| RPH-104 | 1 | 0.1% |
| Fluoxetine | 1 | 0.1% |
| Nomacopan | 1 | 0.1% |
| Desidustat | 1 | 0.1% |
| PLX-PAD | 1 | 0.1% |
| Gemtuzumab ozogamicin | 1 | 0.1% |
| TD139 | 1 | 0.1% |
| Tamoxifen | 1 | 0.1% |
| Secuquinumab | 1 | 0.1% |
| Veru-111 | 1 | 0.1% |
| DFV890 | 1 | 0.1% |
| Azithromycine | 1 | 0.1% |
| ACT12 | 1 | 0.1% |
| BIO101 | 1 | 0.1% |
| iodonated Povidone | 1 | 0.1% |
| Edoxaban | 1 | 0.1% |
| MEDI3506 | 1 | 0.1% |
| ABX464 | 1 | 0.1% |
| Zanubrutinib | 1 | 0.1% |
| Ambrisentan | 1 | 0.1% |
| RESP301 | 1 | 0.1% |
| Apocynin | 1 | 0.1% |
| Bovine Lipid Extract Surfactant | 1 | 0.1% |
| Otilimab | 1 | 0.1% |
| Dornase alfa | 1 | 0.1% |
| Clarithromycin | 1 | 0.1% |
| Deferiprone | 1 | 0.1% |
| ANG-3777 | 1 | 0.1% |
| DeltaRex-G | 1 | 0.1% |
| Dialyzable Leukocyte Extract | 1 | 0.1% |
| Diltiazem | 1 | 0.1% |
| MyVir | 1 | 0.1% |
| Niacin-Tannin | 1 | 0.1% |
| Silymarin | 1 | 0.1% |
| Sodium chloride | 1 | 0.1% |
| Pentoxifylline | 1 | 0.1% |
| Sofosbuvir-Daclatasvir | 1 | 0.1% |
| SAB-185 | 1 | 0.1% |
| Interferon Alpha Gamma | 1 | 0.1% |
| BRII-198 | 1 | 0.1% |
| Thymoquinone | 1 | 0.1% |
| Metronidazole | 1 | 0.1% |
| Interleukin-7 (CYT107) | 1 | 0.1% |
| Vitamin E | 1 | 0.1% |
| Trihexyphenidyl | 1 | 0.1% |
| Decitabine | 1 | 0.1% |
| Alvelestat | 1 | 0.1% |
| Metoprolol | 1 | 0.1% |
| AMY-101 | 1 | 0.1% |
| SCTA01 | 1 | 0.1% |
| ResCure | 1 | 0.1% |
| Apremilast | 1 | 0.1% |
| Isoquercetin | 1 | 0.1% |
| AZD1656 | 1 | 0.1% |
| Degarelix | 1 | 0.1% |
| Plitidepsin | 1 | 0.1% |
| Levilimab | 1 | 0.1% |
| Cospherunate | 1 | 0.1% |
| APL-9 | 1 | 0.1% |
| Fenofibrate | 1 | 0.1% |
| EB05 | 1 | 0.1% |
| LEAF-4L6715 | 1 | 0.1% |
| ND;Phytomedicine | 1 | 0.1% |
| Sodium Nitrite | 1 | 0.1% |
| TXA127 | 1 | 0.1% |
| Abivertinib | 1 | 0.1% |
| LSALT peptide | 1 | 0.1% |
| PTC299 | 1 | 0.1% |
| Pacritinib | 1 | 0.1% |
| STC3141 | 1 | 0.1% |
| Argatroban | 1 | 0.1% |
| Bivalirudin | 1 | 0.1% |
| Dutasteride | 1 | 0.1% |
| Ozanimod | 1 | 0.1% |
| Prasugrel | 1 | 0.1% |
| Aprotinin | 1 | 0.1% |
| SBI-101 | 1 | 0.1% |
| LEAF-4L7520 | 1 | 0.1% |
| M5049 | 1 | 0.1% |
| CYT-107 | 1 | 0.1% |
| STI-1499 | 1 | 0.1% |
| Ampion | 1 | 0.1% |
| Nicotinamide Riboside | 1 | 0.1% |
| Prolastin | 1 | 0.1% |
| Viusid/Asbrip | 1 | 0.1% |
| Epoprostenol | 1 | 0.1% |
| Garadacimab | 1 | 0.1% |
| OP-101 | 1 | 0.1% |
| Merimepodib | 1 | 0.1% |
| RTB101 | 1 | 0.1% |
| Sirukumab | 1 | 0.1% |
| Biomodulin T | 1 | 0.1% |
| Aspirin/dipyridamole | 1 | 0.1% |
| CIGB 300 | 1 | 0.1% |
| Cannabidiol | 1 | 0.1% |
| Clofazimine | 1 | 0.1% |
| CPI-006 | 1 | 0.1% |
| Conestat alfa | 1 | 0.1% |
| Fostamatinib | 1 | 0.1% |
| Masitinib | 1 | 0.1% |
| Interferon-1-beta | 1 | 0.1% |
| LAU-7b | 1 | 0.1% |
| ARGX-117 | 1 | 0.1% |
| TL-895 | 1 | 0.1% |
| Opaganib | 1 | 0.1% |
| TRV027 | 1 | 0.1% |
| PHR160 Spray | 1 | 0.1% |
| Axatilimab | 1 | 0.1% |
| Ramelteon | 1 | 0.1% |
| Bemiparin | 1 | 0.1% |
| Sofusbuvir | 1 | 0.1% |
| Monalizumab | 1 | 0.1% |
| BRII-196 | 1 | 0.1% |
| Brequinar | 1 | 0.1% |
| Edaravone | 1 | 0.1% |
| Infliximab | 1 | 0.1% |
| SnPP Protoporphyrin | 1 | 0.1% |
| Nadroparin | 1 | 0.1% |
| Pentaglobin | 1 | 0.1% |
| MK-5475 | 1 | 0.1% |
| Metenkefalin | 1 | 0.1% |
| Rintatolimod | 1 | 0.1% |
| ATI-450 | 1 | 0.1% |
| Azoximer bromide | 1 | 0.1% |
| Disulfiram | 1 | 0.1% |
| Ibudilast | 1 | 0.1% |
| LMWH | 1 | 0.1% |
| Nangibotide | 1 | 0.1% |
| Mometasone furoate | 1 | 0.1% |
| Sulodexide | 1 | 0.1% |
| Pioglitazone | 1 | 0.1% |
| TY027 | 1 | 0.1% |
| UTTR1147A | 1 | 0.1% |
| BAT2020 | 1 | 0.1% |
| ACT13 | 1 | 0.1% |
| Omegaven | 1 | 0.1% |
| Ifenprodil | 1 | 0.1% |
| Pamrevlumab | 1 | 0.1% |
| XC221 | 1 | 0.1% |
| PB1046 | 1 | 0.1% |
| Bardoxolone | 1 | 0.1% |
| ANIF1 | 1 | 0.1% |
| INM005 | 1 | 0.1% |
| Melphalan | 1 | 0.1% |
| BCc1 nanomedicine | 1 | 0.1% |
| Bucillamine | 1 | 0.1% |
| EC-18 | 1 | 0.1% |
| Beractant | 1 | 0.1% |
| F-652 | 1 | 0.1% |
| Crizanlizumab | 1 | 0.1% |
| Hydroxycloroquine | 1 | 0.1% |
| Granulocyte colony-stimulating factor | 1 | 0.1% |
| Interferon beta 1a | 1 | 0.1% |
| Hep-s | 1 | 0.1% |
| Losmapimod | 1 | 0.1% |
| Hydrochloroquine | 1 | 0.1% |
| Raltagravir | 1 | 0.1% |
| Nelfinavir | 1 | 0.1% |
| Tenecteplase | 1 | 0.1% |
| Teprenone | 1 | 0.1% |
| XAV-19 | 1 | 0.1% |
| Testosterone | 1 | 0.1% |
| Trans sodium crocetinate | 1 | 0.1% |
| Omeprazole | 1 | 0.1% |
| Interferon alpha-1b | 1 | 0.1% |
| Ketamine | 1 | 0.1% |
| Primaquine | 1 | 0.1% |
| CD24Fc | 1 | 0.1% |
| Sofosbuvir/velpatasvir | 1 | 0.1% |
| Triiodothyronine | 1 | 0.1% |
| TAK-981 | 1 | 0.1% |
| Amiodarone | 1 | 0.1% |
| Vafidemstat | 1 | 0.1% |
| Candesartan | 1 | 0.1% |
| Colistin | 1 | 0.1% |
| Tradipitant | 1 | 0.1% |
| BLD-2660 | 1 | 0.1% |
| Lenzilumab | 1 | 0.1% |
| Recombinant Human Angiotensin-converting Enzyme 2 | 1 | 0.1% |
| Bactek-R | 1 | 0.1% |
| Verapamil | 1 | 0.1% |
| Aspririn | 1 | 0.1% |
| LY3127804 | 1 | 0.1% |
| Anti-PD-1(NOS) | 1 | 0.1% |
| ASC09F | 1 | 0.1% |
| Vazegepant | 1 | 0.1% |
| Carrimycin | 1 | 0.1% |
| Senicapoc | 1 | 0.1% |
| Baloxavir Marboxil | 1 | 0.1% |
| Omega3 Viruxide | 1 | 0.1% |
| Celecoxib | 1 | 0.1% |
| Etanercept biosimilar | 1 | 0.1% |
| CSA0001 | 1 | 0.1% |
| Minocycline | 1 | 0.1% |
| Dihydroartemisinin/piperaquine | 1 | 0.1% |
| GNS651 | 1 | 0.1% |
| Fluvoxamine | 1 | 0.1% |
| Interferon alpha 2a | 1 | 0.1% |
| Noscapine | 1 | 0.1% |
| Jaktinib | 1 | 0.1% |
| Recombinant human plasma gelsolin | 1 | 0.1% |
| Meplazumab | 1 | 0.1% |
| FT516 | 1 | 0.1% |
| Dalargin | 1 | 0.1% |
| Sodium Aescinate | 1 | 0.1% |
| AVM0703 | 1 | 0.1% |
| TFF2 | 1 | 0.1% |
| Peg-Interferon alpha-2b | 1 | 0.1% |
| Methotrexate nano-formulation | 1 | 0.1% |
| RBT-9 | 1 | 0.1% |
| Piclidenoson | 1 | 0.1% |
| Interferon(NOS) | 1 | 0.1% |
| Bemcentinib | 1 | 0.1% |
| Amoxicillin-clavulanate | 1 | 0.1% |
| Anti-PD1 mab (unspecified) | 1 | 0.1% |
| XPro1595 | 1 | 0.1% |
| Bismuth potassium citrate | 1 | 0.1% |
| Almitrine | 1 | 0.1% |
| Etoposide | 1 | 0.1% |
| Camrelizumab | 1 | 0.1% |
| Nebulised Rt-PA | 1 | 0.1% |
| Ceftaroline | 1 | 0.1% |
| Itraconazole | 1 | 0.1% |
| Ceftriaxone | 1 | 0.1% |
| Chimeric COVID-19 DC vaccine | 1 | 0.1% |
| Febuxostat | 1 | 0.1% |
| Ebastine | 1 | 0.1% |
| Emapalumab | 1 | 0.1% |
| Emtricitabine | 1 | 0.1% |
| CM4620 | 1 | 0.1% |
| OM-85 | 1 | 0.1% |
| G-CSF | 1 | 0.1% |
| BMS-986253 | 1 | 0.1% |
| GD31 | 1 | 0.1% |
| Teicoplanin | 1 | 0.1% |
| Gimsilumab | 1 | 0.1% |
| Dalteparin | 1 | 0.1% |
| Enalapril | 1 | 0.1% |
| Estrogen patch | 1 | 0.1% |
| Clevudine | 1 | 0.1% |
| Lenalidomide | 1 | 0.1% |
| Interferon-beta1a | 1 | 0.1% |
| Amoxicillin/clavulanate | 1 | 0.1% |
| Ixekizumab | 1 | 0.1% |
| Escin | 1 | 0.1% |
| Levofloxacin | 1 | 0.1% |
| MRx-4DP0004 | 1 | 0.1% |
| Moxifloxacin | 1 | 0.1% |
| Albumin | 1 | 0.1% |
| IFX-1 | 1 | 0.1% |
| Angiotensin-converting Enzyme Inhibitors | 1 | 0.1% |
| AT-001 | 1 | 0.1% |
| Novaferon | 1 | 0.1% |
| Calcifediol | 1 | 0.1% |
| Piperacillin-tazobactam | 1 | 0.1% |
| Naltrexone | 1 | 0.1% |
| Polyinosinic-Polycytidylic Acid | 1 | 0.1% |
| Ramipril | 1 | 0.1% |
| recombinant human IL-2 | 1 | 0.1% |
| Galidesivir | 1 | 0.1% |
| Retinoic acid | 1 | 0.1% |
| Peginterferon lambda-1a | 1 | 0.1% |
| rSIFN-co | 1 | 0.1% |
| Enoxaparin/Lovenox | 1 | 0.1% |
| Solnatide | 1 | 0.1% |
| Tirofiban | 1 | 0.1% |
| Suramin | 1 | 0.1% |
| Zinc chloride | 1 | 0.1% |
| Tenofovir alafenamide | 1 | 0.1% |
| Clindamycin | 1 | 0.1% |
| ASC09/ritonavir | 1 | 0.1% |
| Pyridostigmine | 1 | 0.1% |
| Triazavirin | 1 | 0.1% |
| Aliskiren | 1 | 0.1% |
| Eicosapentaenoic acid | 1 | 0.1% |
| TJ003234 (Anti-GM-CSF Monoclonal Antibody) | 1 | 0.1% |
| vMIP | 1 | 0.1% |
| Primary Endpoint | N | % |
| Efficacy - Clinical improvement (except WHO scale) | 349 | 24.8% |
| Efficacy - Other efficacy (add comment) | 303 | 21.5% |
| Efficacy - Viral load | 181 | 12.8% |
| Efficacy - Mortality | 172 | 12.2% |
| Efficacy - Oxygen parameters | 153 | 10.9% |
| Safety | 116 | 8.2% |
| Efficacy - WHO scale | 110 | 7.8% |
| Other (add comment) | 20 | 1.4% |
| Efficacy - Infection rate (prevention) | 5 | 0.4% |